RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kane Biotech - Stock

Kane Biotech P/S 2024

Kane Biotech P/S

81.06

Ticker

KNE.V

ISIN

CA4838092084

As of Jul 4, 2024, Kane Biotech's P/S ratio stood at 81.06, a 1,693.36% change from the 4.52 P/S ratio recorded in the previous year.

The Kane Biotech P/S history

Kane Biotech Aktienanalyse

What does Kane Biotech do?

Kane Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Kane Biotech's P/S Ratio

Kane Biotech's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Kane Biotech's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Kane Biotech's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Kane Biotech’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Kane Biotech stock

What is the price-to-earnings ratio of Kane Biotech?

The price-earnings ratio of Kane Biotech is currently 81.06.

How has the price-earnings ratio of Kane Biotech changed compared to last year?

The price-to-earnings ratio of Kane Biotech has increased by 1,693.36% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Kane Biotech high compared to other companies?

Yes, the price-to-earnings ratio of Kane Biotech is high compared to other companies.

How does an increase in the price-earnings ratio of Kane Biotech affect the company?

An increase in the price-earnings ratio of Kane Biotech would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Kane Biotech affect the company?

A decrease in the price-earnings ratio of Kane Biotech would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Kane Biotech?

Some factors that influence the price-earnings ratio of Kane Biotech are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Kane Biotech pay?

Over the past 12 months, Kane Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kane Biotech is expected to pay a dividend of 0 CAD.

What is the dividend yield of Kane Biotech?

The current dividend yield of Kane Biotech is .

When does Kane Biotech pay dividends?

Kane Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kane Biotech?

Kane Biotech paid dividends every year for the past 0 years.

What is the dividend of Kane Biotech?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kane Biotech located?

Kane Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kane Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kane Biotech from 7/4/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 7/4/2024.

When did Kane Biotech pay the last dividend?

The last dividend was paid out on 7/4/2024.

What was the dividend of Kane Biotech in the year 2023?

In the year 2023, Kane Biotech distributed 0 CAD as dividends.

In which currency does Kane Biotech pay out the dividend?

The dividends of Kane Biotech are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Kane Biotech

Our stock analysis for Kane Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kane Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.